A Review of Emerging ARNI Data in HFrEF
Published: 27 November 2019
Despite advances in cardiovascular therapy, heart failure (HF) continues to be a leading cause of morbidity and mortality with significant cost to the health care system. Evidence for the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan has demonstrated significant reductions in all-cause mortality, cardiovascular mortality, and HF hospitalization compared with enalapril and international guidelines currently recommend its use.
Despite this evidence and the recommendation of clinical guidelines, ARNI therapy is not initiated in the majority of eligible patients. Evidence suggests a lack of understanding of a patient’s risk and also the benefit of life saving therapies by physicians is a primary cause of under-utilization.
Increased education is needed so clinicians fully understand the patient’s risk, as well as latest mechanistic and clinical data to ensure confidence in using newer therapies.
This educational program summarises new data covering ARNI therapy for heart failure with reduced ejection fraction (HFrEF) presented at the European Society of Cardiology (ESC) 2019 congress.
- Review updated data of ARNI therapy for HFrEF present at the ESC 2019
- Understand the current utilisation of ARNI therapy in HFrEF (guidelines and databases)
- Interpret potential mechanistic data related to the clinical benefit of ARNI therapy including imaging and biomarker data
- Apply new data covering the utilization of ARNI therapy in complex patients including recently decompensated and hospitalized patients.
More from this programme
ARIADNE in Review
|ARIADNE in Review||Watch now|
Commentary on ARIADNE
|Commentary on ARIADNE||Watch now|
PROVE-HF in Review
|PROVE-HF in Review||Watch now|
EVALUATE in Review
|EVALUATE in Review||Watch now|
Commentary on PROVE-HF and EVALUATE
|Commentary on PROVE-HF and EVALUATE||Watch now|
TRANSITION-CHF in Review
|TRANSITION-CHF in Review||Watch now|
PIONEER in Review
|PIONEER in Review||Watch now|
Commentary on TRANSITION-CHF and PIONEER
Andrew JS Coats
Professor of Cardiology and Scientific Director
Prof Coats is Editor-in-Chief of the Cardiac Failure Review journal. He has published over 20 patents, more than 750 full research papers and more than 120,000 career citations and has a personal H-index of 146. Andrew was elected to the Presidential Trio of the Heart Failure Association of the ESC in 2018 and will serve as its president from 2020-2022.
Prof Coats is the Immediate past-President of the Heart Failure Association and past-Professor of Cardiology at the University of Warwick, UK. He has also held posts as Head of Cardiology at Imperial College, London and Associate Medical Director and Director of Cardiology at the Royal Brompton and Harefield Hospitals, London. From 2012 to 2017 he was Director of the Monash-Warwick Alliance, and before that served as Deputy Vice-Chancellor and Dean of Medicine at the University of Sydney.
He is an…
Director, Noninvasive Cardiology / Professor
Prof Scott D Solomon is the Edward D Frohlich Distinguished Chair at Harvard Medical School, Director of Noninvasive Cardiology and Senior Physician at Brigham and Women’s Hospital. His research group has played a leading role in clinical trials in heart failure, hypertension and myocardial infarction.
He received his AB from Williams College and his MD from Harvard Medical School.